Skip to main content


Fig. 2 | Journal for ImmunoTherapy of Cancer

Fig. 2

From: Longitudinal immune characterization of syngeneic tumor models to enable model selection for immune oncology drug discovery

Fig. 2

Changes in immune infiltrate over the course of CT-26 tumor development. (a) Schematic of sample collection. (b) Tumor volumes on indicated day post implant. (c) Proportion of CD45- to CD45+ cells measured at each timepoint by flow cytometry (d) Proportion of CD3+, CD11b, NK, and B-cells as a percent of CD45+ cells (left) or as a percent of live cells (right) measured by flow cytometry. (e) Sunburst blots showing T-cell and NK cell populations as a proportion of CD45+ cells. (f) Sunburst plots showing the proportion of myeloid cell populations as a proportion of CD45+ cells. (g) Flow cytometry data for individual T-cell populations. (h) Flow cytometry data for individual macrophage cell populations. (i) Gene expression data generated from a panel of 96 genes was used to calculate a GSVA score [4, 5] indicating enrichment for specific immune cell types at each timepoint. Flow cytometry data is 1 sample from 7 pooled tumors for day 3, 4 tumors from individual animals and 1 sample from 2 pooled tumors on day 7 and 6 individual tumors from day 14. Sunburst plots show data from a pool of n=6 samples. For GSVA scores day 3 n=4 tumors, day 7 n= 6 tumors, and Day 14 n=5 tumors. Statistical significance is indicated as NS=not significant, *p<0.05, **p<0.01,***p<0.001, ****p<0.0001. Data for sunburst plots available in Additional file 4: Table S4

Back to article page